TALOPH(SH:600222)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 560,317,916.01, representing a year-on-year increase of 32.69%[3] - The net profit attributable to shareholders for Q1 2023 was CNY 3,682,566.68, reflecting a growth of 58.07% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 3,452,841.10, an increase of 40.91% year-on-year[3] - The basic earnings per share for Q1 2023 was CNY 0.0065, up by 58.54% from the previous year[3] - The company reported a net profit of CNY 201,783,788.37 for the first quarter of 2023, compared to CNY 186,609,951.83 in the first quarter of 2022, an increase of 8.1%[13] - The net profit for Q1 2023 was approximately ¥3.29 million, compared to ¥2.17 million in Q1 2022, representing a 51.8% increase[17] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3,572,512,646.95, a decrease of 0.77% from the end of the previous year[4] - The total assets of the company as of March 31, 2023, were CNY 3,572,512,646.95, a slight decrease from CNY 3,600,184,129.95 at the end of 2022[12] - The total liabilities decreased to CNY 1,975,922,301.14 as of March 31, 2023, from CNY 1,986,099,689.13 at the end of 2022, a reduction of 0.6%[13] - The equity attributable to shareholders at the end of Q1 2023 was CNY 1,553,379,373.18, down by 1.09% compared to the end of the previous year[4] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was CNY -92,268,340.56, representing a decrease of 39.29% year-on-year[3] - Cash flow from operating activities showed a net outflow of approximately ¥92.27 million in Q1 2023, an improvement from a net outflow of ¥151.97 million in Q1 2022[19] - Investment activities resulted in a net cash outflow of approximately ¥19.64 million in Q1 2023, compared to a net inflow of ¥63.11 million in Q1 2022[19] Shareholder Information - The company had a total of 62,349 common shareholders at the end of the reporting period[6] - The top shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., held 82,441,168 shares, accounting for 14.37% of the total shares[7] Operational Metrics - The company's cash and cash equivalents decreased to CNY 248,462,111.96 as of March 31, 2023, down from CNY 311,383,783.24 at the end of 2022, a decline of 20.1%[11] - Accounts receivable increased to CNY 744,735,581.99 as of March 31, 2023, compared to CNY 709,294,055.62 at the end of 2022, reflecting a growth of 5.0%[11] - The company's inventory as of March 31, 2023, was CNY 433,230,308.30, down from CNY 450,488,977.16 at the end of 2022, a decrease of 3.8%[11] - Non-current assets totaled CNY 1,589,611,259.02 as of March 31, 2023, compared to CNY 1,568,943,854.70 at the end of 2022, an increase of 1.3%[12] Research and Development - The company incurred research and development expenses of approximately ¥24.19 million in Q1 2023, compared to ¥19.58 million in Q1 2022, marking a 23.5% increase[16] Strategic Initiatives - The company established a pharmaceutical industry fund with a total scale of CNY 400 million, with an initial investment of CNY 120 million completed in January 2023[10] - The company is actively linking with market investment institutions and industry resources to expand its upstream and downstream industrial chain[10] Sales Performance - The company reported a significant increase in sales revenue from goods and services, totaling approximately ¥490.86 million in Q1 2023, compared to ¥355.72 million in Q1 2022, reflecting a 38% increase[18] - Total operating costs for Q1 2023 were approximately ¥558.03 million, up from ¥411.80 million in the same period last year, reflecting a 35.5% increase[16]